Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Compounding botanicals: a legal perspective.

J G Valentino1, F G Bormel

  • 1United States Pharmacopeia (USP), Rockville, Md., USA.

Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)
|September 1, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Black box warnings in prescription drug labeling: results of a survey of 206 drugs.

Food and drug law journal·1999
Same author

New antibiotic standards needed.

Drug intelligence & clinical pharmacy·1987
Same author

Product reporting program.

JAMA·1979
Same author

An analysis of the regulatory and legal aspects of patient package inserts.

Journal of the American Pharmaceutical Association·1977
Same author

A new plan: providing patient inserts in dispensing-size packages.

Hospital formulary·1976
Same author

Doctor, what should pharmacists tell your patients about the drugs you prescribe?

Hospital formulary·1975
Same journal

The Sky is His Wife (2001)/Jim Alford (b. 1943).

Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)·2013
Same journal

Zada Mary cooper (1875-1961).

Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)·2013
Same journal

Aiming for, believing in, and achieving a target a1c of less than 7.

Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)·2013
Same journal

Evaluation of OTC Product Information in Three Drug Information Databases for PDAs.

Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)·2013
Same journal

New biotechnology approvals for 2002.

Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)·2013
Same journal

Preventing meningococcal outbreaks: an opportunity for pharmacists.

Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)·2013
See all related articles

Section 503A of the Federal Food, Drug, and Cosmetic Act clarifies that pharmacy compounding regulations apply to drug products, not dietary supplements or cosmetics. These other products must follow separate federal guidelines.

Area of Science:

  • Pharmaceutical Law
  • Regulatory Science
  • Pharmacy Practice

Background:

  • Pharmacy compounding has historically been regulated by states.
  • Distinguishing compounding from drug manufacturing, regulated by the FDA, has been a challenge.
  • The Food and Drug Administration (FDA) Modernization Act of 1997 introduced Section 503A to address this distinction.

Purpose of the Study:

  • To analyze the impact of Section 503A on the compounding of drugs, dietary supplements, and cosmetics.
  • To clarify the regulatory scope of Section 503A.
  • To differentiate between pharmacy compounding and manufacturing.

Main Methods:

  • Review of the Food and Drug Administration (FDA) Modernization Act of 1997.
  • Analysis of the Federal Food, Drug, and Cosmetic Act.

Related Experiment Videos

  • Examination of the Code of Federal Regulations, Federal Register, and FDA Guidances.

    • Main Results:

    • Section 503A specifically addresses the compounding of drug products.
    • The law distinguishes between state-regulated pharmacy compounding and FDA-regulated drug manufacturing.
    • Section 503A does not directly apply to the compounding of botanicals, which may be classified as dietary supplements or cosmetics.

    Conclusions:

    • Section 503A governs compounded products intended for drug use.
    • Compounded dietary supplements and cosmetics fall outside the scope of Section 503A.
    • Products for dietary supplement and cosmetic use must comply with distinct federal regulations, including good manufacturing practices and labeling requirements.